In 2006, what vaccine was licensed by the FDA to prevent cervical cancer?

The vaccine licensed by the FDA in 2006 to prevent cervical cancer is the Human papillomavirus (HPV) vaccine. This vaccine specifically targets certain strains of the HPV virus, which are known to be the primary cause of cervical cancer. By immunizing against these high-risk HPV types, the vaccine significantly reduces the risk of developing cervical abnormalities that could lead to cancer.

Cervical cancer is linked to persistent infections with certain types of HPV, particularly HPV types 16 and 18. The introduction of the HPV vaccine has been a crucial step in public health efforts aimed at reducing the incidence of cervical cancer and improving women's health outcomes.

The other vaccines listed do not focus on cervical cancer prevention. For instance, the Hepatitis B vaccine prevents liver infections that can lead to liver cancer, while the Measles, Mumps, and Rubella vaccine protects against viral infections unrelated to cervical cancer. The Influenza vaccine is designed to prevent seasonal flu and has no effect on preventing cancer. Thus, the Human papillomavirus vaccine stands out as the correct choice for specifically preventing cervical cancer.